IL-JSSI
14.12.2021 16:57:07 CET | Business Wire | Press release
Jet Support Services, Inc. (JSSI), the leading independent provider of maintenance support and financial services to the business aviation industry, today announced the acquisition of TRAXXALL. Founded in 2013, TRAXXALL provides software-as-a-service (“SaaS”) solutions for aircraft maintenance tracking, parts inventory management, and cloud-based software to enhance aircraft maintenance, repair and overhaul (MRO) workflow. Headquartered in Montreal, Canada, TRAXXALL has offices around the world.
TRAXXALL has quickly emerged as a significant player in the maintenance tracking market. Named by the Financial Times as one of the Americas’ fastest growing companies, TRAXXALL delivers software to help customers reduce aircraft downtime, improve data accuracy, and have comprehensive visibility over maintenance costs, parts inventory, and MRO operations.
“JSSI and TRAXXALL have a shared history of challenging the status quo and putting customers first,” said Neil Book, CEO of JSSI. “This business combination presents an exciting opportunity to deliver huge value to our customers and dramatically accelerate the growth trajectory for both companies.”
TRAXXALL’s global team will join JSSI’s growing SaaS division, which comprises previous acquisition SierraTrax, reporting to Ash Reddy, recently promoted to the position of chief operating officer at JSSI.
“We take great pride in our reputation in the business aviation market as a thought partner and maintenance advisor to a robust and diverse fleet of aircraft around the world,” said Reddy. “As we now combine TRAXXALL with JSSI’s core products and data, we are confident in our ongoing business mission to add tangible value for aircraft owners, operators, and maintenance facilities.”
“I am so incredibly proud of what the Traxxall team has achieved,” said Scott Henderson, CEO of TRAXXALL. “I could not think of a better long-term partner for our business than the team at JSSI.”
“JSSI’s values are firmly aligned with our own and will allow us to further develop and enhance our suite of products,” added Mark Steinbeck, president of TRAXXALL. “With direct access to JSSI’s data and capabilities, we will rapidly grow the maintenance tracking business alongside the SierraTrax brand and deliver advanced maintenance tracking solutions to a wider cross section of the business aviation community.”
In addition to its growing maintenance tracking software business, JSSI provides aircraft parts, engines and APUs to hundreds of operators across all makes and models through its JSSI Parts & Leasing business and offers a range of digital tools through Conklin & de Decker to help customers benchmark and compare aircraft ownership options with the most accurate performance and comparison data available. This move to develop the company’s maintenance tracking offering further establishes JSSI as the go-to source for business aviation intelligence and support for the entire aircraft life cycle.
GTCR, a leading private equity firm, is a majority investor in JSSI.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211214005652/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom